BioCentury | Feb 11, 2016
Distillery Therapeutics

Therapeutics: Downstream regulatory element antagonistic modulator (DREAM); ATP-dependent potassium channel (KATP)

...A/S markets NovoNorm, a short-acting β-cell stimulating meglitinide that inhibits KATP, to treat diabetes. TARGET/MARKER/PATHWAY: Downstream regulatory element antagonistic modulator (DREAM)...
BioCentury | Nov 1, 2010
Company News

Apeiron Biologics, Evotec deal

...will use its preclinical screening technologies and assay development to evaluate small molecule modulators of downstream regulatory element antagonistic modulator (DREAM)...
BioCentury | Jun 10, 2010
Distillery Therapeutics

Indication: Neurology

...Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Nerve damage; neurology; stroke Downstream regulatory element antagonistic modulator (DREAM); NMDAR...
Items per page:
1 - 3 of 3